Semaglutide for Weight Loss: Complete Guide

Quick Answer

Semaglutide produces an average 14.9% body weight loss over 68 weeks at the 2.4 mg dose (Wegovy). It works by activating GLP-1 receptors in the brain and gut to reduce appetite and slow digestion. It's a once-weekly subcutaneous injection, FDA-approved for obesity as Wegovy. Clinical results are among the best ever documented for a weight loss medication.

What Is Semaglutide?

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist developed by Novo Nordisk. It's the active ingredient in:

Ozempic — 0.5, 1, or 2 mg weekly injection; FDA-approved for type 2 diabetes
Wegovy — 2.4 mg weekly injection; FDA-approved for chronic weight management
Rybelsus — 7 or 14 mg oral tablet; FDA-approved for type 2 diabetes

For weight loss, Wegovy (2.4 mg) is the designated formulation. However, Ozempic is frequently prescribed off-label for weight loss — often at doses up to 2 mg.

How Semaglutide Causes Weight Loss

Semaglutide mimics the natural GLP-1 hormone at sustained, pharmacologic levels. The key mechanisms:

Hypothalamic activation: Binds to GLP-1 receptors in the brain's hunger-control center, reducing appetite-stimulating neuron activity. Most patients describe dramatically reduced food cravings and "food noise."

Gastric slowing: Delays stomach emptying, producing earlier and longer satiety after meals.

Reward circuit modulation: Reduces the dopamine response to food, particularly high-calorie foods, decreasing the motivation to eat beyond hunger.

Natural GLP-1 lasts ~2 minutes in the body. Semaglutide has a 7-day half-life, maintaining continuous receptor activation across the dosing week.

Clinical Trial Results: The STEP Program

The STEP trial program established semaglutide's weight loss evidence base in five large trials:

STEP 1 (n=1,961, no diabetes):

Semaglutide: -14.9% body weight at 68 weeks
86% of patients lost ≥5%
69% lost ≥10%
50% lost ≥15%

STEP 3 (added intensive behavioral intervention):

Semaglutide: -16.0% — confirming that lifestyle amplifies results

STEP 5 (104-week follow-up):

-15.2% maintained at 2 years — confirms durability

SELECT (2023, cardiovascular outcomes):

20% reduction in major cardiovascular events (heart attack, stroke, CV death)
Semaglutide approved for cardiovascular risk reduction in obesity

Dosing and Titration

Weeks	Wegovy Dose
1–4	0.25 mg
5–8	0.5 mg
9–12	1.0 mg
13–16	1.7 mg
17+	2.4 mg (maintenance)

The titration takes 16 weeks to reach full dose. Maximum weight loss is achieved 12–18 months into treatment.

Side Effects

Common (>10%): Nausea, diarrhea, vomiting, constipation, abdominal pain. These are most prominent in the first 4–12 weeks and diminish significantly over time.

Serious (rare): Pancreatitis, gallbladder disease, acute kidney injury (usually from severe dehydration due to vomiting), diabetic retinopathy progression in people with diabetes.

Contraindicated in: Personal or family history of medullary thyroid carcinoma; multiple endocrine neoplasia type 2; prior hypersensitivity to semaglutide.

Cost and Access

List price for Wegovy: Approximately $1,350/month (US, 2025)

With manufacturer savings card (Novo Nordisk): As low as $25/month for commercially insured patients who meet eligibility.

Without insurance: $800–1,400/month depending on source. Compounded semaglutide from 503B registered facilities has been a lower-cost option, though FDA access restrictions tightened in 2025.

Telehealth access: Ro, Hims/Hers, Found, and other platforms offer online evaluation and prescription in most US states.

Get a Semaglutide Prescription Online

Bottom Line

Semaglutide is one of the two most effective weight loss medications ever approved. At 2.4 mg weekly, it produces approximately 15% average body weight loss — results that typically take 12–18 months to fully achieve. It's safe, well-studied, and accessible via telehealth for most qualifying patients.